In a recent interview, Sriram Krishnan, the outgoing artificial intelligence adviser to the White House, stated that the Trump administration will not pursue formal licensing or a regulatory framework for AI technologies. He emphasized that the administration is committed to avoiding bureaucratic hurdles that could impede innovation, asserting, "There will not be an FDA for AI." This stance aligns with a broader deregulatory approach that has characterized the administration's policies since its inception. Krishnan's comments come on the heels of significant federal interventions, including a controversial decision to halt the rollout of advanced AI models from companies like Anthropic and OpenAI, highlighting the tension between regulatory oversight and technological advancement.

The administration's hands-off approach has sparked a mixed response, with some critics arguing that it has contributed to a growing public backlash against AI technologies. Recent research indicates that a majority of Americans favor stricter regulations on AI, reflecting widespread concerns about its implications for privacy, security, and employment. Notably, local opposition has led to the suspension of over 75 data center projects in just the first quarter of this year, illustrating the challenges that AI companies face in navigating public sentiment.

Despite the regulatory uncertainty, companies across various sectors are increasingly adopting AI technologies, albeit with caution. A recent report from PYMNTS Intelligence reveals that while firms are embedding AI into their operations for tasks like research and document generation, they are largely restricting its autonomous capabilities. This trend suggests a careful approach to AI deployment, prioritizing oversight and control over full automation. As businesses seek to leverage AI's potential, they remain wary of ceding too much power to these systems, reflecting a broader hesitance in the market.

Source: PYMNTS